AHEALTH Stock Overview
Apex Healthcare Berhad, an investment holding company, engages in the development, manufacture, marketing, and distribution of pharmaceutical and healthcare products.
No risks detected for AHEALTH from our risk checks.
Apex Healthcare Berhad Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||RM2.77|
|52 Week High||RM3.20|
|52 Week Low||RM2.38|
|1 Month Change||-6.42%|
|3 Month Change||-3.15%|
|1 Year Change||-10.65%|
|3 Year Change||28.24%|
|5 Year Change||135.75%|
|Change since IPO||814.41%|
Recent News & Updates
|AHEALTH||MY Pharmaceuticals||MY Market|
Return vs Industry: AHEALTH exceeded the MY Pharmaceuticals industry which returned -25.5% over the past year.
Return vs Market: AHEALTH underperformed the MY Market which returned -8.7% over the past year.
|AHEALTH Average Weekly Movement||3.7%|
|Pharmaceuticals Industry Average Movement||3.6%|
|Market Average Movement||5.5%|
|10% most volatile stocks in MY Market||11.5%|
|10% least volatile stocks in MY Market||2.9%|
Stable Share Price: AHEALTH is less volatile than 75% of MY stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: AHEALTH's weekly volatility (4%) has been stable over the past year.
About the Company
Apex Healthcare Berhad, an investment holding company, engages in the development, manufacture, marketing, and distribution of pharmaceutical and healthcare products. It operates through three segments: Manufacturing and Marketing, Wholesale and Distribution, and Corporate. The company offers a range of products, including cough mixture and antihistamine, anti-infective, anti-diabetic, anti-hypertensive, neuromuscular agent, analgesic, dermatological, and ophthalmological products in the form of tablets, capsules, oral liquids and suspensions, creams, and sterile eye drops under the Xepa brand name.
Apex Healthcare Berhad Fundamentals Summary
|AHEALTH fundamental statistics|
Is AHEALTH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AHEALTH income statement (TTM)|
|Cost of Revenue||RM638.01m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||0.13|
|Net Profit Margin||7.84%|
How did AHEALTH perform over the long term?See historical performance and comparison
2.0%Current Dividend Yield
Is AHEALTH undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AHEALTH?
Other financial metrics that can be useful for relative valuation.
|What is AHEALTH's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does AHEALTH's PE Ratio compare to its peers?
|AHEALTH PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
DPHARMA Duopharma Biotech Berhad
KOTRA Kotra Industries Berhad
YSPSAH Y.S.P. Southeast Asia Holding Berhad
RHONEMA Rhone Ma Holdings Berhad
AHEALTH Apex Healthcare Berhad
Price-To-Earnings vs Peers: AHEALTH is expensive based on its Price-To-Earnings Ratio (20.9x) compared to the peer average (13.4x).
Price to Earnings Ratio vs Industry
How does AHEALTH's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?
Price-To-Earnings vs Industry: AHEALTH is expensive based on its Price-To-Earnings Ratio (20.9x) compared to the MY Pharmaceuticals industry average (13.9x)
Price to Earnings Ratio vs Fair Ratio
What is AHEALTH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||20.9x|
|Fair PE Ratio||20.6x|
Price-To-Earnings vs Fair Ratio: AHEALTH is expensive based on its Price-To-Earnings Ratio (20.9x) compared to the estimated Fair Price-To-Earnings Ratio (20.6x).
Share Price vs Fair Value
What is the Fair Price of AHEALTH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: AHEALTH (MYR2.77) is trading above our estimate of fair value (MYR1.3)
Significantly Below Fair Value: AHEALTH is trading above our estimate of fair value.
Price to Earnings Growth Ratio
PEG Ratio: AHEALTH is poor value based on its PEG Ratio (3.6x)
Discover undervalued companies
How is Apex Healthcare Berhad forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AHEALTH's forecast earnings growth (5.8% per year) is above the savings rate (3.6%).
Earnings vs Market: AHEALTH's earnings (5.8% per year) are forecast to grow slower than the MY market (9.9% per year).
High Growth Earnings: AHEALTH's earnings are forecast to grow, but not significantly.
Revenue vs Market: AHEALTH's revenue (5.1% per year) is forecast to grow slower than the MY market (5.2% per year).
High Growth Revenue: AHEALTH's revenue (5.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AHEALTH's Return on Equity is forecast to be low in 3 years time (12.3%).
Discover growth companies
How has Apex Healthcare Berhad performed over the past 5 years?
Past Performance Score4/6
Past Performance Score 4/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AHEALTH has high quality earnings.
Growing Profit Margin: AHEALTH's current net profit margins (7.8%) are higher than last year (7.8%).
Past Earnings Growth Analysis
Earnings Trend: AHEALTH's earnings have grown by 7.2% per year over the past 5 years.
Accelerating Growth: AHEALTH's earnings growth over the past year (18.3%) exceeds its 5-year average (7.2% per year).
Earnings vs Industry: AHEALTH earnings growth over the past year (18.3%) underperformed the Pharmaceuticals industry 21.4%.
Return on Equity
High ROE: AHEALTH's Return on Equity (12.1%) is considered low.
Discover strong past performing companies
How is Apex Healthcare Berhad's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: AHEALTH's short term assets (MYR448.5M) exceed its short term liabilities (MYR147.4M).
Long Term Liabilities: AHEALTH's short term assets (MYR448.5M) exceed its long term liabilities (MYR20.4M).
Debt to Equity History and Analysis
Debt Level: AHEALTH has more cash than its total debt.
Reducing Debt: AHEALTH's debt to equity ratio has increased from 0% to 2.7% over the past 5 years.
Debt Coverage: AHEALTH's debt is well covered by operating cash flow (462.3%).
Interest Coverage: AHEALTH earns more interest than it pays, so coverage of interest payments is not a concern.
Discover healthy companies
What is Apex Healthcare Berhad current dividend yield, its reliability and sustainability?
Dividend Score 3/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: AHEALTH's dividend (1.99%) isn’t notable compared to the bottom 25% of dividend payers in the MY market (2.15%).
High Dividend: AHEALTH's dividend (1.99%) is low compared to the top 25% of dividend payers in the MY market (4.94%).
Stability and Growth of Payments
Stable Dividend: AHEALTH's dividend payments have been volatile in the past 10 years.
Growing Dividend: AHEALTH's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (41.2%), AHEALTH's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonable cash payout ratio (70.3%), AHEALTH's dividend payments are covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Kirk Kee (59 yo)
Dr. Kirk Chin Kee has been the Chief Executive Officer and Chairman of Apex Healthcare Berhad since May 19, 2010 and served as its Managing Director since March 3, 2000. He has been Executive Director of A...
CEO Compensation Analysis
Compensation vs Market: Kirk's total compensation ($USD65.75K) is below average for companies of similar size in the MY market ($USD333.71K).
Compensation vs Earnings: Kirk's compensation has been consistent with company performance over the past year.
Experienced Management: AHEALTH's management team is seasoned and experienced (7.9 years average tenure).
Experienced Board: AHEALTH's board of directors are seasoned and experienced ( 10.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Apex Healthcare Berhad's employee growth, exchange listings and data sources
- Name: Apex Healthcare Berhad
- Ticker: AHEALTH
- Exchange: KLSE
- Founded: 1962
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: RM1.288b
- Shares outstanding: 477.17m
- Website: https://www.apexhealthcare.com.my
Number of Employees
- Apex Healthcare Berhad
- 1-5, Jalan TTC 1
- Cheng Industrial Estate
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/27 00:00|
|End of Day Share Price||2022/06/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.